Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Hospira
Hospira
Activities:
Drug Delivery
Pharmaceutical
A global specialty pharmaceutical and medication delivery company.
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
FDA cautions Pfizer subsidiary in India in quality control warning letter
The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery
Mylan and Hospira voluntarily recall injectables
Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory
Brussels explains why it approved Pfizer/Hospira deal
Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory
Hospira calls for biosimilars to have same name as biologicals
Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development
Hospira and Pfenex link up to develop Lucentis biosimilar
Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery
Pfizer to acquire Hospira
Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing
Opinion: Still not getting it right
The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now